Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.

There is increasing evidence that deficient clearance of β-amyloid (Aβ) contributes to its accumulation in late-onset Alzheimer disease (AD). Several Aβ-degrading enzymes, including neprilysin (NEP), endothelin-converting enzyme (ECE) and angiotensin-converting enzyme (ACE) reduce Aβ levels and prot...

Full description

Bibliographic Details
Main Authors: James Scott Miners, Jen ePalmer, Hannah eTayler, Emma eAshby, Laura ePalmer, Patrick eKehoe, Seth eLove
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-09-01
Series:Frontiers in Aging Neuroscience
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fnagi.2014.00238/full
_version_ 1819171529005465600
author James Scott Miners
Jen ePalmer
Hannah eTayler
Emma eAshby
Laura ePalmer
Patrick eKehoe
Seth eLove
author_facet James Scott Miners
Jen ePalmer
Hannah eTayler
Emma eAshby
Laura ePalmer
Patrick eKehoe
Seth eLove
author_sort James Scott Miners
collection DOAJ
description There is increasing evidence that deficient clearance of β-amyloid (Aβ) contributes to its accumulation in late-onset Alzheimer disease (AD). Several Aβ-degrading enzymes, including neprilysin (NEP), endothelin-converting enzyme (ECE) and angiotensin-converting enzyme (ACE) reduce Aβ levels and protect against cognitive impairment in mouse models of AD. In post-mortem human brain tissue we have found that the activity of these Aβ-degrading enzymes rise with age and increases still further in AD, perhaps as a physiological response that helps to minimize the build-up of Aβ. ECE-1/-2 and ACE are also rate-limiting enzymes in the production of endothelin-1 (ET-1) and angiotensin II (Ang II), two potent vasoconstrictors, increases in the levels of which are likely to contribute to reduced blood flow in AD. This review considers the possible interdependence between Aβ-degrading enzymes, ischemia and Aβ in AD: ischemia has been shown to increase Aβ production both in vitro and in vivo, whereas increased Aβ probably enhances ischemia by vasoconstriction, mediated at least in part by increased ECE and ACE activity. In contrast, NEP activity may help to maintain cerebral perfusion, by reducing the accumulation of Aβ in cerebral blood vessels and lessening its toxicity to vascular smooth muscle cells. In assessing the role of Aβ-degrading proteases in the pathogenesis of AD and, particularly, their potential as therapeutic agents, it is important to bear in mind the multifunctional nature of these enzymes and to consider their effects on other substrates and pathways.
first_indexed 2024-12-22T19:52:44Z
format Article
id doaj.art-e54a24f27ccc4cbab9a34a05880ee398
institution Directory Open Access Journal
issn 1663-4365
language English
last_indexed 2024-12-22T19:52:44Z
publishDate 2014-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Aging Neuroscience
spelling doaj.art-e54a24f27ccc4cbab9a34a05880ee3982022-12-21T18:14:30ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652014-09-01610.3389/fnagi.2014.00238109379Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.James Scott Miners0Jen ePalmer1Hannah eTayler2Emma eAshby3Laura ePalmer4Patrick eKehoe5Seth eLove6University of Bristol, UKUniversity of Bristol, UKUniversity of Bristol, UKUniversity of Bristol, UKUniversity of Bristol, UKUniversity of Bristol, UKUniversity of Bristol, UKThere is increasing evidence that deficient clearance of β-amyloid (Aβ) contributes to its accumulation in late-onset Alzheimer disease (AD). Several Aβ-degrading enzymes, including neprilysin (NEP), endothelin-converting enzyme (ECE) and angiotensin-converting enzyme (ACE) reduce Aβ levels and protect against cognitive impairment in mouse models of AD. In post-mortem human brain tissue we have found that the activity of these Aβ-degrading enzymes rise with age and increases still further in AD, perhaps as a physiological response that helps to minimize the build-up of Aβ. ECE-1/-2 and ACE are also rate-limiting enzymes in the production of endothelin-1 (ET-1) and angiotensin II (Ang II), two potent vasoconstrictors, increases in the levels of which are likely to contribute to reduced blood flow in AD. This review considers the possible interdependence between Aβ-degrading enzymes, ischemia and Aβ in AD: ischemia has been shown to increase Aβ production both in vitro and in vivo, whereas increased Aβ probably enhances ischemia by vasoconstriction, mediated at least in part by increased ECE and ACE activity. In contrast, NEP activity may help to maintain cerebral perfusion, by reducing the accumulation of Aβ in cerebral blood vessels and lessening its toxicity to vascular smooth muscle cells. In assessing the role of Aβ-degrading proteases in the pathogenesis of AD and, particularly, their potential as therapeutic agents, it is important to bear in mind the multifunctional nature of these enzymes and to consider their effects on other substrates and pathways.http://journal.frontiersin.org/Journal/10.3389/fnagi.2014.00238/fullCerebral Amyloid AngiopathyEndothelin-1NeprilysinAlzheimer’s disease.angiotensin-converting enzymecerebral hypoperfusion
spellingShingle James Scott Miners
Jen ePalmer
Hannah eTayler
Emma eAshby
Laura ePalmer
Patrick eKehoe
Seth eLove
Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.
Frontiers in Aging Neuroscience
Cerebral Amyloid Angiopathy
Endothelin-1
Neprilysin
Alzheimer’s disease.
angiotensin-converting enzyme
cerebral hypoperfusion
title Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.
title_full Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.
title_fullStr Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.
title_full_unstemmed Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.
title_short Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.
title_sort aβ degradation or cerebral perfusion divergent effects of multifunctional enzymes
topic Cerebral Amyloid Angiopathy
Endothelin-1
Neprilysin
Alzheimer’s disease.
angiotensin-converting enzyme
cerebral hypoperfusion
url http://journal.frontiersin.org/Journal/10.3389/fnagi.2014.00238/full
work_keys_str_mv AT jamesscottminers abdegradationorcerebralperfusiondivergenteffectsofmultifunctionalenzymes
AT jenepalmer abdegradationorcerebralperfusiondivergenteffectsofmultifunctionalenzymes
AT hannahetayler abdegradationorcerebralperfusiondivergenteffectsofmultifunctionalenzymes
AT emmaeashby abdegradationorcerebralperfusiondivergenteffectsofmultifunctionalenzymes
AT lauraepalmer abdegradationorcerebralperfusiondivergenteffectsofmultifunctionalenzymes
AT patrickekehoe abdegradationorcerebralperfusiondivergenteffectsofmultifunctionalenzymes
AT sethelove abdegradationorcerebralperfusiondivergenteffectsofmultifunctionalenzymes